| Patent application number | Description | Published |
|---|
| 20080227083 | OPTICAL DETECTOR FOR ENZYME ACTIVATION - Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy, at the second and third wavelengths. | 09-18-2008 |
| 20090131276 | DIAGNOSTIC KITS AND METHODS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 05-21-2009 |
| 20090136954 | GENETIC MARKERS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel genetic markers useful in assessing the risk of SCD, or SCA, and kits containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 05-28-2009 |
| 20100047915 | IDENTIFYING PATIENTS AT RISK FOR LIFE THREATENING ARRHYTHMIAS - The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed. | 02-25-2010 |
| 20100098207 | METHOD AND DEVICE TO PRODUCE HEAT AND POWER - A method and device are described to form a heat producing plant with replaceable fusion-based reaction cartridges, where the fuel is embedded in casings in the preferred embodiment, and the heat can be converted into electrical or mechanical energy. The replaceable unit consists of sheets containing individual heating elements that are addressed sequentially to trigger the heat producing reactions. A controller governs the triggering activity until all the elements are used. The resulting heat can be converted into mechanical energy using turbines and into electrical energy using the Seebeck effect. This inventive device can be used in mobile environments as well as at fixed locations where heat, mechanical power or electricity are needed. | 04-22-2010 |
| 20100317006 | SCA RISK STRATIFICATION BY PREDICTING PATIENT RESPONSE TO ANTI-ARRHYTHMICS - Genetic tests and methods for treatment based on markers to identify patients suffering from life-threatening ventricular tachy-arrhythmias, such as Ventricular Tachycardias (“VT”) and Ventricular Fibrillation (“VF”) that might lead to Sudden Cardiac Arrest (“SCA”) or Sudden Cardiac Death (“SCD”) are provided. Patients who cannot be sufficiently protected by medication alone, such as those refractory to anti-arrhythmic medication, are identified based on their genotype. The resulting information is used in a diagnostic test to identify and treat those patients who would benefit from the implantation of an Implantable Cardio Defibrillator (“ICD”). | 12-16-2010 |
| 20110071589 | WAVEFORMS FOR ELECTRICAL STIMULATION THERAPY - In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In one example, the disclosure relates to a method including delivering a series of pulses with alternating pulse polarities to a gastrointestinal tract of a patient. The series of pulses includes at least a first pulse of a first polarity, a second pulse of a second polarity, and a third pulse of the first polarity, where the first, second and third pulses are delivered in direct succession and in that order. The first and second pulses are separated by a first time delay and the second and third pulses are separated by a second time delay. In some examples, each of the first and second time delays depend on the frequency that the series of pulses are delivered. | 03-24-2011 |
| 20110143345 | Genetic Markers for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel genetic markers useful in assessing the risk of SCD or SCA and compositions containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught. | 06-16-2011 |
| 20110143956 | Diagnostic Kits and Methods for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel diagnostic kits, DNA microarrays, and methods employing these genetic markers are used in assessing the risk of SCD or SCA. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught. | 06-16-2011 |
